PRKAB1: A Protein Target for Drug Development (G5564)

Target Name: PRKAB1

NCBI ID: G5564

PRKAB1

PRKAB1: A Protein Target for Drug Development

PRKAB1 (PRK-尾1) is a protein that is expressed in various tissues throughout the body, including muscle, heart, and brain. It is a key regulator of theAMP-activated protein (AMP) kinase (AMPK), which is a critical signaling pathway that regulates a wide range of cellular processes, including muscle growth, inflammation, and stress resistance.

Recent studies have identified PRKAB1 as a potential drug target for a variety of diseases, including muscle wasting, myopathies, and neurodegenerative disorders. Its role in AMP-activated signaling has also been implicated in a number of diseases, including cancer, cardiovascular disease, and neuropsychiatric disorders.

PRKAB1 is a 21-kDa protein that is expressed in muscle, heart, brain, and other tissues. It is one of four known isoforms of PRKAB1, which are generated by alternative splicing of the same gene. The most abundant isoform is a protein that has 119 amino acid residues at its C-terminus, known as PRKAB1-AS1. The other isoforms have up to 21 amino acid residues longer.

PRKAB1 is a key regulator of theAMP-activated protein (AMP) kinase (AMPK), which is a critical signaling pathway that regulates a wide range of cellular processes, including muscle growth, inflammation, and stress resistance. AMP is a small molecule that is generated by the breakdown of a protein called GAMMA-activated protein (GAP) by the G protein-coupled receptor (GPCR) PRKAB1. When GAP is broken down, AMP is produced and can then stimulate the activity of various cellular signaling pathways.

PRKAB1 has been shown to play a critical role in the regulation of AMP-activated signaling in various tissues. For example, studies have shown that PRKAB1 is involved in the regulation of muscle growth and maintenance, as well as the regulation of inflammation and stress resistance. It has also been shown to be involved in the regulation of neurotransmitter release and the modulation of pain perception.

In addition to its role in AMP-activated signaling, PRKAB1 has also been implicated in a number of diseases. For example, it has been shown to be involved in the development and progression of cancer, including breast cancer. It has also been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Given its involvement in a wide range of cellular processes, PRKAB1 has been identified as a potential drug target for a variety of diseases. Studies have shown that inhibiting the activity of PRKAB1 can have beneficial effects on a wide range of cellular processes, including muscle growth, inflammation, and stress resistance.

In addition to its potential therapeutic applications, PRKAB1 has also been the subject of intense research in the hopes of identifying new biomarkers for a variety of diseases. Studies have shown that PRKAB1 is a sensitive target for small molecules, including inhibitors of the activity of various signaling pathways. This suggests that PRKAB1 may be an attractive target for the development of new drugs for a wide range of diseases.

In conclusion, PRKAB1 is a protein that is expressed in various tissues throughout the body and plays a critical role in the regulation of AMP-activated signaling. Its role in this signaling pathway has been implicated in a wide range of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. As a result, PRKAB1 has emerged as a promising drug target for the development of new treatments for these diseases. Further research is needed to fully understand the role of PRKAB1 in cellular signaling and to identify new biomarkers for its role in disease.

Protein Name: Protein Kinase AMP-activated Non-catalytic Subunit Beta 1

Functions: Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3)

The "PRKAB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKAB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets